[quote]The positive recommendation by the FDA Cancer Drugs Advisory Committee brings carfilzomib a step closer to being licensed and marketed as a treatment for relapsed and/or refractory myeloma patients in America. A final decision by the FDA is expected by the end of July 2012. The FDA approval of carfilzomib should hopefully be followed by its approval by the FDA?s European counterpart, the European Medicines Agency (EMA), later in the year. 😀
Eric Low, Chief Executive of Myeloma UK said, ?This is great news for the myeloma community. As myeloma is largely a relapsing, remitting cancer, it is very important that the next treatment is always available. If these next treatments are both more effective and have fewer side-effects, then this is very important for patients. I sincerely hope the final decision is positive and that European approval follows soon.?[/quote]
So, [b] Carfilzomib[/b] looks like it will soon be joining us in the fight against MM. The sooner the better to my mind. It is a cousin of [b]Velcade[/b]… but with better results and much gentler side-effects by all accounts. I know that I have been pushing [b]Carfilzomib/Kyprolis[/b] to the fore recently.. but I truly believe it will me a major step forward for us and the general fight against MM. 😎 😀 🙂
Bring it on… quickly please.;-)
Dai.
[b]Footnote:[/b]
Produced by the US Pharmaceuticals company [b]Onyx[/b], when fully licensed [b]Carfilzomib[/b] will be traded as [b]'Kyprolis'[/b].
The quoted section above is part of the news of [b]Carfilzomib/Kyprolis[/b] to be found in the [b]'Home'[/b] section of this site.